LNP 509
LNP 509 is a selective I1 imidazoline receptor ligand with a bovine pKi value of 6.27. LNP 509 exists mainly in the form of a more stable imine tautomer. Intracisternal administration of LNP 509 in anesthetized rabbits induces a dose-dependent decrease in mean arterial blood pressure. LNP 509 can be used in hypertension-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 773839-36-4
- Formel: C13H22N2
- Molecular Weight:206.33
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
LNP 509 (compound 1e) (10-9 to 10-4 M; 40 min) binds to bovine chromaffin cell I1 imidazoline receptors with a pKi of 6.27 and exhibits no detectable affinity for I2 imidazoline binding sites or α2-adrenoceptors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 773839-36-4
-
Molecular Weight 206.33
-
Formel C13H22N2
-
SMILES
CC1CC(NC(C2CC2)C3CC3)=NC1C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
LNP 509 Related Classifications
HY-188065 Related Classifications
Powered by Bioz